Torrent Pharmaceuticals gets observations from USFDA for Indrad plant
26th Apr 2019

Torrent Pharmaceuticals has received certain observations from the US Food and Drug Administration (USFDA) for Indrad Plant which are procedural in nature and the company is confident of addressing them satisfactorily. The audit at Indrad Plant of the company was carried out by USFDA in the month of April, 2019.

Torrent Pharmaceuticals is Flagship Company of the Torrent group, a leader in cardiovascular and central nervous system segments. It also has presence in gastro-intestinal, diabetology, anti-infective and pain management segments.